Profile data is unavailable for this security.
About the company
Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
- Revenue in GBP (TTM)857.70m
- Net income in GBP-105.44m
- Incorporated2014
- Employees1.05k
- LocationIndivior PLC10710 Midlothian TurnpikeSuite 125, North ChesterfieldCHESTERFIELD 23235United StatesUSA
- Phone+0 (804) 379-1090
- Websitehttps://www.indivior.com/en
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Zhejiang Hisun Pharmaceutical Co., Ltd. | 1.02bn | -8.25m |
Collegium Pharmaceutical Inc | 431.16m | 74.69m |
Calliditas Therapeutics AB | 118.67m | -35.60m |
ANI Pharmaceuticals Inc | 402.97m | 17.16m |
Kissei Pharmaceutical Co Ltd | 407.14m | 63.10m |
Innoviva Inc | 247.11m | 108.73m |
Indivior PLC | 857.70m | -105.44m |
Aurisco Pharmaceutical Co Ltd | 153.63m | 40.75m |
Tarsus Pharmaceuticals Inc | 62.34m | -112.21m |
Changchun BCHT Biotechnology Co | 200.86m | 56.23m |
Polypeptide Group AG | 273.17m | -23.84m |
KPC Pharmaceuticals Inc | 798.44m | 48.07m |
KAKEN PHARMACEUTICAL CO., LTD. | 379.37m | 38.22m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Two Seas Capital LPas of 20 Jun 2024 | 13.26m | 9.98% |
Morgan Stanley & Co. International Plcas of 31 Dec 2023 | 9.74m | 7.33% |
Oaktree Capital Management LPas of 09 Jul 2024 | 9.38m | 7.06% |
Soci�t� G�n�rale Gestion SAas of 02 Jul 2024 | 6.77m | 5.09% |
Scopia Capital Management LPas of 19 Mar 2024 | 6.29m | 4.73% |
Fidelity Management & Research Co. LLCas of 31 Jul 2024 | 5.13m | 3.87% |
Barclays Capital Securities Ltd.as of 30 Jun 2024 | 4.64m | 3.49% |
Madison Avenue Partners LPas of 14 Nov 2023 | 4.63m | 3.48% |
The Vanguard Group, Inc.as of 31 Aug 2024 | 4.59m | 3.45% |
BlackRock Investment Management (UK) Ltd.as of 31 Aug 2024 | 3.87m | 2.91% |